BioCryst Pharmaceuticals: Angioedemas, Hereditary trials

The registry lists 22 Angioedemas, Hereditary studies with BioCryst Pharmaceuticals as lead sponsor. 2 are open to participants now and 8 have results posted.

Phase 1 8Phase 2 7Phase 3 9No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Long-Term Study of Navenibart in Participants With Hereditary AngioedemaEnrolling by invitationNCT07204938Phase 3
• Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat StudiesEnrolling by invitationNCT04933721Phase 3
• A Study of Navenibart (STAR-0215) in Participants With Hereditary AngioedemaCompletedNCT05695248Phase 1/2Results posted
• Berotralstat Treatment in Children With Hereditary AngioedemaActive, not recruitingNCT05453968Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in JapanCompletedNCT03873116Phase 3Results posted
• Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAECompletedNCT03485911Phase 3Results posted
• A Long Term Safety Study of BCX7353 in Hereditary AngioedemaCompletedNCT03472040Phase 2/3Results posted
• Study of BCX7353 as a Treatment for Attacks of Hereditary AngioedemaCompletedNCT03240133Phase 2Results posted
• Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary AngioedemaCompletedNCT02870972Phase 2Results posted
• 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE AttacksCompletedNCT02303626Phase 2/3Results posted
• A Study of Navenibart in Participants With Hereditary AngioedemaActive, not recruitingNCT06842823Phase 3
• A Long-term Study of STAR-0215 in Participants With Hereditary AngioedemaActive, not recruitingNCT06007677Phase 2
• A Study of STAR-0215 in Healthy Adult ParticipantsCompletedNCT05477160Phase 1
• Oral Berotralstat Expanded Access ProgramApproved for marketingNCT04428632
• A Relative Bioavailability Study of Two Formulations of BCX7353CompletedNCT03202784Phase 1
• A Drug-Drug Interaction Study to Evaluate Drug Transporter InteractionsCompletedNCT03136237Phase 1
• An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe SubstratesCompletedNCT02819102Phase 1
• Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary AngioedemaTerminatedNCT02670720Phase 3
• First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese VolunteersCompletedNCT02448264Phase 1
• Study to Determine How BCX4161 is Metabolized and Eliminated by the BodyCompletedNCT02218294Phase 1
• A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161CompletedNCT02125162Phase 1
• Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAECompletedNCT01984788Phase 2